A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)

  • Koch, Alvaro (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date7/7/086/30/11